XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock - XOMAO STOCK NEWS

Q: What financial results did XOMA report for the first quarter of 2024?

XOMA recorded total revenues of $1.5 million, increased R&amp;D expenses, and achieved a net loss of $8.6 million for the quarter.

Welcome to our dedicated page for XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock news (Ticker: XOMAO), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock stock.

XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (symbol: XOMAO) is a biotechnology royalty aggregator specializing in acquiring future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company has an extensive portfolio of assets, including licenses for therapeutic candidates designed to improve human health. XOMA's recent achievements include earning milestone payments related to FDA approvals, acquiring economic interests in various assets, and initiating share buyback programs.

05/09/2024 07:30 AM

News

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Rhea-AI Summary

XOMA reported its first quarter 2024 financial results, earning a $9 million milestone with the FDA approval of OJEMDA™, gaining $9.5 million from Kinnate acquisition, expanding its portfolio, and initiating a $50 million stock repurchase program. The company also reported $1.5 million in total revenues for Q1 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.08%

Tags

04/30/2024 07:30 AM

News

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Rhea-AI Summary

XOMA has acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for $22 million upfront. The assets include XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream. XACIATO™ is FDA-approved for treating bacterial vaginosis, with commercial activities initiated by Organon in 2023. XOMA aims to create additional value for shareholders with these acquisitions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/25/2024 07:30 AM

News

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Rhea-AI Summary

XOMA (NASDAQ: XOMA) has earned a $9 million milestone following the FDA's accelerated approval of Day One Biopharmaceuticals' NDA for OJEMDA™ (tovorafenib), a treatment for pediatric low-grade glioma. XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales. This marks a significant advancement in providing treatment for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

04/03/2024 09:00 AM

News

XOMA Corporation Announces Closing of Tender Offer

Rhea-AI Summary

XOMA successfully completed its tender offer to acquire all outstanding shares of Kinnate Biopharma Inc., offering $2.5879 per share in cash plus a contingent value right. The offer included the right to receive 85% of net proceeds from any out license or sale of Kinnate programs within a year of the merger and 100% of net proceeds from the sale of certain assets to Pierre Fabre Laboratories.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.18%

Tags

03/21/2024 07:30 AM

News

XOMA Declares Quarterly Preferred Stock Dividends

Rhea-AI Summary

XOMA (Nasdaq: XOMA) announces cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of Series A to receive $0.53906 per share, and Series B holders to receive $0.52344 per depositary share.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.44%

Tags

03/19/2024 04:05 PM

News

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Rhea-AI Summary

XOMA is set to acquire Kinnate Biopharma Inc., adding $9.5 million in cash to its balance sheet and expanding its early-stage programs. The merger agreement includes a cash price per share of $2.5879 for Kinnate stockholders, with the Offer extended until April 2, 2024. The acquisition is subject to certain conditions and is expected to close in April 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.16%

Tags

03/08/2024 07:30 AM

News

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

Rhea-AI Summary

XOMA Corporation reported strong financial results for Q4 and full year 2023, highlighted by raising $140 million in non-dilutive capital, adding a new commercial asset to their portfolio, and achieving key milestones with partners. The company ended the year with a robust cash position, anticipating significant clinical and regulatory events in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.43%

Tags

02/28/2024 07:30 AM

News

XOMA to Present at Upcoming Investor Conferences in March

Rhea-AI Summary

XOMA Corporation announces participation in upcoming investor conferences in March 2024, with key executives presenting at TD Cowen Health Care Conference and Leerink Partners Global Biopharma Conference.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.37%

Tags

02/16/2024 08:00 AM

News

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Rhea-AI Summary

XOMA Corporation announced the acquisition of Kinnate Biopharma Inc. for a base cash price of $2.3352 per share, potentially adding $9.5 million in cash to its balance sheet. The deal includes a contingent value right (CVR) and aims to enhance XOMA's royalty portfolio. The acquisition is expected to close in April 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.4%

Tags

01/18/2024 08:30 AM

News

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Rhea-AI Summary

XOMA Corporation acquires economic interest in DSUVIA® from Talphera, Inc. for $8 million, with a 15% royalty on commercial sales and a significant portion of the 75% royalty from U.S. Department of Defense purchases. XOMA is entitled to no less than 50% of the potential $116.5 million in milestone payments. DSUVIA® received Milestone C approval from the U.S. Department of Defense for use in U.S. Army sets, kits, and outfits (SKOs) and was added to the DoD Joint Deployment Formulary in September 2020. XOMA will receive 100% of all royalties and milestones related to DSUVIA® sales until the Company receives $20 million, after which XOMA fully retains the 15% royalty associated with DSUVIA® commercial sales.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.43%

Tags

FAQ

What is the current stock price of XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO)?

The current stock price of XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO) is $25.35 as of January 29, 2025.

What does XOMA Corporation specialize in?

XOMA is a biotechnology royalty aggregator that acquires future economics associated with pre-commercial therapeutic candidates.

What recent achievements has XOMA had?

XOMA has earned milestone payments from FDA approvals, acquired economic interests in assets, and initiated share buyback programs.

What is XOMA's extensive portfolio comprised of?

XOMA's portfolio includes licenses for therapeutic candidates aimed at improving human health.

What is unique about XOMA's approach to capital deployment?

XOMA focuses on accelerating value creation with a disciplined approach to capital deployment.

What significant event has XOMA recently experienced related to FDA approvals?

XOMA has recouped its initial capital outlay and anticipates future royalties from OJEMDA™, a therapy for relapsed or refractory pLGG driven by BRAF fusions.

How does XOMA support biotech companies?

XOMA provides non-dilutive, non-recourse funding to biotech companies by acquiring future economics associated with their licensed therapeutic candidates.

What financial results did XOMA report for the first quarter of 2024?

XOMA recorded total revenues of $1.5 million, increased R&D expenses, and achieved a net loss of $8.6 million for the quarter.

What recent acquisitions has XOMA made?

XOMA acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for an upfront payment of $22 million.

How does XOMA plan to drive sustainable free cash flow generation?

XOMA anticipates that future royalties, including those from OJEMDA™, will contribute to a growing portfolio of royalty receipts supporting sustainable free cash flow generation.

What sets XOMA apart in the biotechnology industry?

XOMA's focus on acquiring future economics from licensed therapeutic candidates and providing funding to biotech companies sets it apart in the industry.